These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 17939047

  • 1. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.
    Ann Hepatol; 2009 Mar; 8(3):207-11. PubMed ID: 19841499
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K.
    J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
    [Abstract] [Full Text] [Related]

  • 7. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [Abstract] [Full Text] [Related]

  • 8. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [Abstract] [Full Text] [Related]

  • 9. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K.
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
    [Abstract] [Full Text] [Related]

  • 10. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K, CONFIRM Study Investigators.
    N Engl J Med; 2021 Mar 04; 384(9):818-828. PubMed ID: 33657294
    [Abstract] [Full Text] [Related]

  • 11. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H, Chawla Y.
    J Gastroenterol Hepatol; 2011 Jan 04; 26 Suppl 1():109-14. PubMed ID: 21199521
    [Abstract] [Full Text] [Related]

  • 12.  Hepatorenal syndrome: Current concepts related to diagnosis and management.
    de Mattos ÁZ, de Mattos AA, Méndez-Sánchez N.
    Ann Hepatol; 2016 Jan 04; 15(4):474-81. PubMed ID: 27236146
    [Abstract] [Full Text] [Related]

  • 13. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
    Fabrizi F, Dixit V, Messa P, Martin P.
    Int J Artif Organs; 2009 Mar 04; 32(3):133-40. PubMed ID: 19440988
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M, Gluud LL, Bendtsen F, Møller S, Krag AA.
    Ugeskr Laeger; 2013 May 27; 175(22):1562-6. PubMed ID: 23721840
    [Abstract] [Full Text] [Related]

  • 16. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
    Sagi SV, Mittal S, Kasturi KS, Sood GK.
    J Gastroenterol Hepatol; 2010 May 27; 25(5):880-5. PubMed ID: 20074149
    [Abstract] [Full Text] [Related]

  • 17. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
    Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P, Terlipressin Study Group.
    Liver Transpl; 2011 Nov 27; 17(11):1328-32. PubMed ID: 21837734
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A, Borup T, Møller S, Bendtsen F.
    Adv Ther; 2008 Nov 27; 25(11):1105-40. PubMed ID: 19018483
    [Abstract] [Full Text] [Related]

  • 19. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
    Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU.
    United European Gastroenterol J; 2019 May 27; 7(4):529-537. PubMed ID: 31065370
    [Abstract] [Full Text] [Related]

  • 20. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M.
    Eur J Gastroenterol Hepatol; 2002 Dec 27; 14(12):1363-8. PubMed ID: 12468959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.